ABSTRACT
Colorectal cancer incidence rates vary geographically and have changed over time. Notably, in the past two decades, the incidence of early-onset colorectal cancer, affecting individuals under the age of 50 years, has doubled in many countries. The reasons for this increase are unknown. Here, we investigate whether mutational processes contribute to geographic and age-related differences by examining 981 colorectal cancer genomes from 11 countries. No major differences were found in microsatellite unstable cancers, but variations in mutation burden and signatures were observed in the 802 microsatellite-stable cases. Multiple signatures, most with unknown etiologies, exhibited varying prevalence in Argentina, Brazil, Colombia, Russia, and Thailand, indicating geographically diverse levels of mutagenic exposure. Signatures SBS88 and ID18, caused by the bacteria-produced mutagen colibactin, had higher mutation loads in countries with higher colorectal cancer incidence rates. SBS88 and ID18 were also enriched in early-onset colorectal cancers, being 3.3 times more common in individuals diagnosed before age 40 than in those over 70, and were imprinted early during colorectal cancer development. Colibactin exposure was further linked to APC driver mutations, with ID18 responsible for about 25% of APC driver indels in colibactin-positive cases. This study reveals geographic and age-related variations in colorectal cancer mutational processes, and suggests that early-life mutagenic exposure to colibactin-producing bacteria may contribute to the rising incidence of early-onset colorectal cancer.
Competing Interest Statement
io9, has equity and receives income. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. L.B.A. is also a compensated member of the scientific advisory board of Inocras. L.B.A.'s spouse is an employee of Hologic, Inc. E.N.B. is a consultant for io9, has equity, and receives income. A.A. and L.B.A. declare U.S. provisional patent application filed with UCSD with serial number 63/366,392. E.N.B. and L.B.A. declare U.S. provisional patent application filed with UCSD with serial numbers 63/269,033. L.B.A. also declares U.S. provisional applications filed with UCSD with serial numbers: 63/289,601; 63/412,835; as well as an international patent application PCT/US2023/010679. L.B.A. is also an inventor of a US Patent 10,776,718 for source identification by non-negative matrix factorization. M.R.S. is founder, consultant, and stockholder for Quotient Therapeutics. L.B.A., M.D.-G., P.B., S.P., M.R.S., and S. Moody declare a European patent application with application number EP25305077.7. T.D.L. is a co-founder and CSO of Microbiotica. All other authors declare that they have no competing interests.
Funding Statement
This work was delivered as part of the Mutographs team supported by the Cancer Grand Challenges partnership funded by Cancer Research UK (C98/A24032). Work at UC San Diego was also supported by the US National Institute of Health (NIH) grants R01ES032547-01, R01CA269919-01, and 1U01CA290479-01 to L.B.A. as well as by L.B.A.'s Packard Fellowship for Science and Engineering. The research performed in L.B.A.'s lab was further supported by UC San Diego Sanford Stem Cell Institute. This work was supported in part by an IARC Fellowship Award to Wellington Oliveira dos Santos through The Mark Foundation for Cancer Research. Work at the IARC/WHO was also supported by regular budget funding. Work at the Wellcome Sanger Institute was also supported by the Wellcome Trust (grants 206194 and 220540/Z/20/A). Work at Masaryk Memorial Cancer Institute, Brno, Czech Republic, was supported by MH CZ - DRO (MMCI, 00209805). Porto Alegre center in Brazil received support from Hospital de Clinicas de Porto Alegre and Fundacao Medica do Rio Grande do Sul. Barretos Cancer Hospital, in Brazil, was also supported by the Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer). This work was supported by grants from Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) (JP 24ck0106800h0002 to T.S.) and the National Cancer Center Research and Development Fund (2023-A-05 to T.S.). Work at Sinai Health System, Toronto, Canada received support from the NIH (grant U01CA167551). The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approvals were obtained from each Local Research Ethics Committee and Federal Ethics Committee as listed below. The study was submitted and approved by the IARC Ethics Committee (IEC Project 17-10). Informed consent was obtained from all participants. Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina A.C. Camargo Cancer Center, Sao Paulo, Brazil Barretos Cancer Hospital, Barretos, Brazil Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, Rio Grande do Sul, Brazil Ontario Tumour Bank, Ontario Institute for Cancer Research, Toronto, ON, Canada Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada University Health Network, Toronto, ON, Canada Terry Fox National Tumor Bank (Banco Nacional de Tumores Terry Fox), National Cancer Institute, Bogota, Colombia Charles University, Prague, Czech Republic Tehran University of Medical Sciences, Tehran, Iran Golestan University of Medical Sciences, Gorgan, Iran National Cancer Center Research Institute, Chuo-ku, Japan Nofer Institute of Occupational Medicine, Lodz, Poland The Maria Sklodowska-Cure National Research Institute of Oncology, Warsaw, Poland N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russia University Clinical Centre of Serbia, Belgrade, Serbia National Cancer Institute, Bangkok, Thailand Chiang Mai University, Chiang Mai, Thailand Prince of Songkla University, Hat Yai, Thailand
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos